Promising medication combination to treat an 'undruggable' type of lung cancer

AI Summary

Scientists in Manchester have identified a new drug combination targeting a rare KRAS mutation in non-small cell lung cancer (NSCLC), which could improve treatment outcomes for thousands globally. This breakthrough offers hope for patients suffering from a difficult-to-treat subtype of lung cancer responsible for significant cancer mortality worldwide.

Breakthrough research led by scientists in Manchester has identified a new drug combination that could improve outcomes for thousands of patients with lung cancer driven by a rare type of KRAS mutation, offering hope for patients worldwide with this difficult-to-treat subtype of lung cancer. The study published in Cancer Discovery focuses on non-small cell lung cancer (NSCLC), which accounts for around 20% of cancer-related deaths worldwide. Mutations in the KRAS gene are one of the most common causes of NSCLC.